Synergy Bafoon on Call

Quote

I agree..... I think the legacy sales folks should not be referred to as sales reps. They should be referred to as educators. Coffee is for closers and the legacy folks are not drink coffee.
 

There is no way to know how things are going to shake out in the near future. Take things at face value and do your job and if a great career opportunity arises go for it. BMS said they consider us in launch until you are at least one year out. Why would they make wholesale changes before then. Even with all four groups we would only be on a level playing field with numbers when compared to Novo and other DPP-4 forces.

As for Synergy vs. Legacy. There are a lot of top notch reps on both sides with substantial diabetes knowledge and relationships. Most "good" Legacy reps treat Synergy as equals. There are also slackers on both sides that either don't work hard or just are not very good. The same with every company, good and bad.
 
Amylin reps launched GLP-1 to the world. We educated our clients on the MOA, and it was a road we paved for all other companies....namely Novo Nordisk. Novo comes into the mix and slowly takes the market share. At best, it's was a 60/40 advantage with Victoza. However, Amylin maintained a strong presence, and with Bydureon and tenacity of Amylin reps, the ratio is now almost 50/50. It's an amazing thing when you think about it. This little company (Amylin) keeping up with the GIANT Novo, and doing it with far less (money, people, marketing, etc). At last count there were roughly 15 Novo reps in the territory I cover. And yet, they have a minimal advantage in TRx. Their advantage in market share occurred about six months. However, the trend is obvious with the Bydureon launch that their advantage is slowly going away. We will take back the GLP-1 share (Byetta/Bydureon) in the near future. Guess what? This great accomplishment without question goes into the camp of Legacy.
 
Anonymous said:
Amylin reps launched GLP-1 to the world. We educated our clients on the MOA, and it was a road we paved for all other companies....namely Novo Nordisk. Novo comes into the mix and slowly takes the market share. At best, it's was a 60/40 advantage with Victoza. However, Amylin maintained a strong presence, and with Bydureon and tenacity of Amylin reps, the ratio is now almost 50/50. It's an amazing thing when you think about it. This little company (Amylin) keeping up with the GIANT Novo, and doing it with far less (money, people, marketing, etc). At last count there were roughly 15 Novo reps in the territory I cover. And yet, they have a minimal advantage in TRx. Their advantage in market share occurred about six months. However, the trend is obvious with the Bydureon launch that their advantage is slowly going away. We will take back the GLP-1 share (Byetta/Bydureon) in the near future. Guess what? This great accomplishment without question goes into the camp of Legacy.
Click to expand...


Correction: sorry I made a mistake, I meant Lilly reps launched GLP-1... my bad!
 
Bottom line all contract reps are reps that are "rented" to a company for a short period of time to do whatever the company wants them to until their "lease" is up..... I think being a contract rep is great for those that are unemployed and need a paycheck for a short period of time.. Everyone knows that being hired full time as a sales professional is the better deal, but not everyone has that opportunity.. Why contract reps have an issue with full time reps is beyond me.. Dont hate on a sales team that was hired by a company instead "contracting" It's not our fault that you're contract reps, that is what you chose to do, so don't put us down by saying we couldnt sell without a contract sales team that was for BREADTH only to reach out to lower tiered physicians... Thanks for getting out to the doc's that werent writing any GLP-1's and that no one was reaching out to-- it helped the company's objective which is good for everyone...
 
Pharma sales is all contract sales. Some are just quicker than others, but at the end of the day your time goes as your products sales and patent go. No need to belittle a contract rep, we're all in the same position right now.
 
Bottom line the Amylin rep's could not sell a jelly doughnut to a diabetic on a sugar trip. Face it your gravy train is over, BMS doesn't care you have xyz of experience educating your doc's and never closing the deal by selling them. Novo is selling, that's the difference between the two.
 
Anonymous said:
Bottom line the Amylin rep's could not sell a jelly doughnut to a diabetic on a sugar trip. Face it your gravy train is over, BMS doesn't care you have xyz of experience educating your doc's and never closing the deal by selling them. Novo is selling, that's the difference between the two.
Click to expand...

Blow me.
 
Anonymous said:
Bottom line the Amylin rep's could not sell a jelly doughnut to a diabetic on a sugar trip. Face it your gravy train is over, BMS doesn't care you have xyz of experience educating your doc's and never closing the deal by selling them. Novo is selling, that's the difference between the two.
Click to expand...

I didn't feel like throwing up, until I read this. Are you the same dim wit that says he/she can "SELL?" People like you have been closing offices to reps for a decade now. Great job.
 
Anonymous said:
Bottom line the Amylin rep's could not sell a jelly doughnut to a diabetic on a sugar trip. Face it your gravy train is over, BMS doesn't care you have xyz of experience educating your doc's and never closing the deal by selling them. Novo is selling, that's the difference between the two.
Click to expand...

What the hell is a "diabetic on a sugar trip." Are you from 1980?
 


Write your reply...
Top Bottom
Back
Quote